E.R.A. (Education, Response & Access)

Education, Response and Access (ERA)

Have you come here looking for help with a drug habit? We want you to know that we are here for you. We will assist you and help you achieve your goal, and we offer free services and resources to do it! Harm Reduction Services provides effective evidence-based treatment options, and the ERA (Education, Response and Access) program was created to assist people who use drugs in a non-judgmental, practical manner. Our goal is to improve every participant’s quality of life while promoting health and wellness; from assessments, personalized treatment plans, AOD referrals, and assistance in accessing treatment with in-person support for individuals attempting to access Sacramento County AOD System of Care, as well as community support, our case manager will walk you through the often-confusing drug treatment system.

The ERA case manager can also assist you with signing up for Medi-Cal and getting all the documents you might need to access treatment, such as a CA i.d. or your Medi-Cal card. In addition to these services, your case manager can provide transportation assistance, if needed. Most importantly, your case manager will advocate for you throughout the entire process, ensuring that you feel supported and heard.

For those individuals struggling to quit using opiates on their own, MAT programs are available. Medications used in the MAT include, Buprenorphine; unlike methadone treatment, which must be performed in a highly structured clinic, buprenorphine is the first medication to treat opioid dependency that is permitted to be prescribed or dispensed in physician offices, significantly increasing treatment access. In the midst of the opioid epidemic, communities across the country face increased demands for substance use services. To combat this crisis, behavioral health organizations are increasingly utilizing evidence-based practices such as medication-assisted treatment (MAT). Medications such as buprenorphine consistently prove effective in treating opioid use disorder. In recent years, extended-release naltrexone has also been approved for the treatment of opioid dependence and shown evidence of effectiveness. The use of naloxone has also become an increasingly important component of local efforts to combat opioid overdose and death. Increasing access to these and other medications and services is critical to stemming the tide of this current epidemic. If you need help or more information, please reach out to the ERA case manager at 916-236-7311.